ALFA Finder| Margins | Investing in energy efficiency; 3.8 Cr capital investment for efficiency. |
|---|---|
| Management confidence | High regarding sustainability goals and decarbonization journey. |
Growth
Achieved 73% reduction in carbon emissions vs FY21 base. Renewable energy share in total mix reached 63% in FY25.
Outlook
Targets carbon neutral operations by 2030 and 100% renewable power by 2030. Planned ESG risk screening for critical suppliers by FY2027.
Risks
Identified climate-related risks and water stress; 20% of freshwater requirement is sourced from water-stressed regions.
Last quarter's promises, checked
Delivered
- Guided R&D 2.5-3% of sales → delivered 2.8% (= BEAT)
- Guided EBITDA margin 25-26% → delivered 25.4% (= BEAT)
- Guided capex ~5% of revenue → delivered 5.2% (= BEAT)
Partly delivered
- Guided double-digit OTC growth → delivered 9% for FY26 (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,645.60
- Market cap
- ₹1,09,275 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 48.7×Sector 43.8×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Other Announcement
Mankind Pharma Limited received an ESG rating of 64.8 from SES ESG Research. This rating was independently assigned for FY26 based on publicly available information.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
- Call
- Guides 20% growth
Mankind Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.